Searching...
12 results for “biotech strategy”
...biotech, that's what I mean. Other people think it refers to biologics, and it's true.
7:30 / 8:31
from transcript7:30 – 8:31
...Biotech, they are trying to cure cancer, make us thinner. Obviously, clip ones have become a big thing. Grow biofuels and make us all look better. You know, trying to do all these different things and doing it in all sorts of different ways. Russell
6:06 / 7:07
from transcript6:06 – 7:07
...Biotech, they are trying to cure cancer, make us thinner. Obviously, clip ones have become a big thing.
5:22 / 6:21
from transcript5:22 – 6:21
...have a huge biotech industry. These are kind of like the, you might call them the the farm league of big of big pharma. They're the ones that come up with the new drugs. Of course, the pharmas are still doing their own work too, and so biotechs becom
6:43 / 7:51
from transcript6:43 – 7:51
...biotech. Most biotech companies never make money. Most biotech companies exist to be externalized r and d for big pharma to take an idea or an asset, bring it to a value inflection point. You see some efficacy. You show it's safe. You have a compound
6:00 / 7:02
from transcript6:00 – 7:02
...typical biotech company is like a bag of options, and each one of the drugs that the company is working on in success could be worth billions of dollars, but that's ten years away, often minimum. And so you're trying to price things based on their ul
9:38 / 10:55
from transcript9:38 – 10:55
...biotech, and they think that what's about to change is it's gonna go the way of the tech industry. And the next big companies are gonna be started by really clever 21 year olds coming out of Stanford. And that hypothesis, people have been testing now
17:55 / 19:04
from transcript17:55 – 19:04
...biotech paradox. One fifth of public biotech companies are trading below their cash balances. Sea brands have hit record lows. The industry spends 2,000,000,000 per approved drug and that number keeps climbing. And yet, we're designing antibodies fro
0:36 / 1:45
from transcript0:36 – 1:45
...ago that biotech was gonna be a focus area for them for decades to come. And so they've put their money where their mouth was and have invested significantly over the past several years in investing in their internal infrastructure to do basic bio ce
19:33 / 20:37
from transcript19:33 – 20:37
...biotechs. You know, for the core members of the research community here, is is that a threat?
45:05 / 46:09
from transcript45:05 – 46:09
...startups, which are the ones supplying the drugs, biotech startups now make two thirds of the drugs that go to market, we have this,
14:08 / 15:27
from transcript14:08 – 15:27
...biotech and farm industry is, you know, how are they able to do it at this pace? Are they able to do it at this cost? Why do their data packages look so good? Right? They have safety. They have tox. They have all these IND enabling studies. You know,
45:46 / 46:57
from transcript45:46 – 46:57
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.